PROTEZ PROGRESSES WITH ANTIBIOTIC COMPOUND DEVELOPMENT

Protez Pharmaceuticals intends to accelerate development of its lead compound SMP-601, a potent injectable antibiotic with a uniquely broad spectrum of activity against both drug resistant gram-positive and many gram negative-pathogens.

Preclinical data suggest that SMP-601 could be a critically important new weapon in the fight against the growing incidence of hospital-based infections that do not respond to existing treatments, the firm said.